## RESEARCH

## **Open Access**



# Trial-level characteristics associate with treatment effect estimates: a systematic review of meta-epidemiological studies

Huan Wang<sup>1†</sup>, Jinlu Song<sup>1†</sup>, Yali Lin<sup>1</sup>, Wenjie Dai<sup>1</sup>, Yinyan Gao<sup>1</sup>, Lang Qin<sup>1</sup>, Yancong Chen<sup>1</sup>, Wilson Tam<sup>2</sup>, Irene XY Wu<sup>1,3\*</sup> and Vincent CH Chung<sup>4,5</sup>

## Abstract

**Background:** To summarize the up-to-date empirical evidence on trial-level characteristics of randomized controlled trials associated with treatment effect estimates.

**Methods:** A systematic review searched three databases up to August 2020. Meta-epidemiological (ME) studies of randomized controlled trials on intervention effect were eligible. We assessed the methodological quality of ME studies using a self-developed criterion. Associations between treatment effect estimates and trial-level characteristics were presented using forest plots.

**Results:** Eighty ME studies were included, with 25/80 (31%) being published after 2015. Less than one-third ME studies critically appraised the included studies (26/80, 33%), published a protocol (23/80, 29%), and provided a list of excluded studies with justifications (12/80, 15%). Trials with high or unclear (versus low) risk of bias on sequence generation (3/14 for binary outcome and 1/6 for continuous outcome), allocation concealment (11/18 and 1/6), double blinding (5/15 and 2/4) and smaller sample size (4/5 and 2/2) significantly associated with larger treatment effect estimates. Associations between high or unclear risk of bias on allocation concealment (5/6 for binary outcome and 1/3 for continuous outcome), double blinding (4/5 and 1/3) and larger treatment effect estimates were more frequently observed for subjective outcomes. The associations between treatment effect estimates and non-blinding of outcome assessors were removed in trials using multiple observers to reach consensus for both binary and continuous outcomes. Some trial characteristics in the Cochrane risk-of-bias (RoB2) tool have not been covered by the included ME studies, including using validated method for outcome measures and selection of the reported results from multiple outcome measures or multiple analysis based on results (e.g., significance of the results).

**Conclusions:** Consistently significant associations between larger treatment effect estimates and high or unclear risk of bias on sequence generation, allocation concealment, double blinding and smaller sample size were found. The impact of allocation concealment and double blinding were more consistent for subjective outcomes. The methodological and reporting quality of included ME studies were dissatisfactory. Future ME studies should follow the corresponding reporting guideline. Specific guidelines for conducting and critically appraising ME studies are needed.

<sup>†</sup>Huan Wang and Jinlu Song are joint first authors.

\*Correspondence: irenexywu@csu.edu.cn

<sup>1</sup> 5/F, Xiangya School of Public Health, No. 238, Shang-ma-yuan-ling Alley, Kaifu district, Changsha, China Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/A.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords:** Meta-epidemiological study, Randomized controlled trial, Systematic review, Treatment effect estimates, Trial-level characteristic

## Background

Randomized controlled trial (RCT) is regarded as the best reliable study design for evaluating the efficacy or effectiveness of healthcare interventions [1, 2]. The results of RCTs could be the cornerstone of supporting clinical practice and improving public health policy decision [1]. However, defects in the design, conduct, analysis, interpretation and report have a substantial impact on the internal validity of RCTs, further distort the results of systematic reviews based on them, and ultimately cause inappropriate clinical decisions [3-5]. For example, a large body of empirical evidence has indicated that high or unclear risk of bias on allocation concealment [6-8], lack of blinding [2, 8, 9], smaller sample size [4, 10, 11], and single center trial [5, 12] showed larger treatment effect estimates. Therefore, it is urgent to identify these factors that could contort treatment effect estimates so as to ensure the authenticity of conclusions drawn from RCTs by scientifically rigorous design and methodology [8].

Based on the results of meta-analyses, meta-epidemiological (ME) study is a method of exploring the influence of specific trial-level characteristic on treatment effect estimates [12]. The Cochrane risk-of-bias (RoB) tool, which is widely used for assessing the risk of bias of RCTs, was developed based on evidence generated from ME studies [13, 14]. Related systematic reviews of ME studies have been published in 2016 with literature search date up to May 2015 [15, 16]. However, an increasing number of ME studies have been published after May 2015, which have not been included in the previous systematic reviews [15, 16]. Some of those newly published ME studies showed inconsistent results on the associations between treatment effect estimates and triallevel characteristics, such as drop out [17, 18], Medline indexed [4, 19] and double blinding [described as double blinding or  $\geq 2$  key parties (participants, personnel, outcome assessors) were blinded] [8, 20], while other newly published ME studies explored additional trial-level characteristics, which have not been investigated by the previous ME studies, neither did they have been covered by the previous systematic reviews accordingly [15, 16] (e.g., trial protocol registration [3, 21] and patient – reported outcome measures) [22]. So it is necessary for us to update the evidence.

This systematic review aimed to 1) summarize the empirical evidence regarding ME studies that investigated the associations between trial-level characteristics of RCTs and treatment effect estimates; 2) inform future best practice in RCT design as well as to provide empirical evidence for updating critical appraisal tool (e.g., The Cochrane RoB tool) for RCT; 3) describe characteristics of ME studies and methods used for the critical appraisal of ME studies, which will serve as a foundation for further development.

#### Methods

#### Protocol and registration

We performed and reported this systematic review with reference to guidance from the Cochrane Handbook for Systematic Reviews of Interventions [13] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations [23]. The protocol of this study was registered on the PROSPERO (CRD42020200947).

#### **Eligibility criteria**

A ME study of RCTs, which assessed the efficacy, effectiveness or safety of an intervention was eligible, and the intervention can be therapeutic or preventive (e.g., vaccines). We only included ME study if it examined the differences in treatment effect estimates stratified by variation in trial-level characteristics (e.g., method of allocation concealment). There were no restrictions on language and publication date.

We excluded ME studies that compared treatment effect estimates between RCTs and observational studies. ME studies comparing treatment effect estimates according to different quantitative methodological quality scores of RCTs (e.g., Jadad scale, ranged from 0 to 5 scores) were excluded as such method has been abandoned [24]. Conference abstracts, protocols, animal experiments, commentary, editorial or statistical methodology papers, and ME studies based on a single metaanalysis were excluded, as well. The most up-to-date version was included if the same ME study was published in different journals or was updated, with the remaining versions being regarded as supplementary sources for data extraction and critical appraisal.

#### Literature search

Related systematic reviews [15, 16] have been published in 2016, which have conducted comprehensive literature search and identified eligible ME studies published before 2015. By adopting the common practice of previous updated systematic reviews [25, 26], we referred to the search strategies of previous systematic review [15] and searched PubMed, Embase, and Web of science with "meta-epidemiology", "treatment effect" and related keywords from January 2015 to August 2020. Reference lists of previously published systematic reviews [15, 16] as well as the identified ME studies were screened for additional studies. Although basing on the literature search results from the previous systematic reviews [15, 16] is a post-hoc decision, we believe it is an optimal choice in terms of saving time, manpower and resources without much (if any) compromising of the comprehensiveness of literature identification. Detailed search strategies were shown in Additional file 1: Appendix 1.

#### Study selection and data extraction

All the retrieved citations were screened firstly based on titles and abstracts, and full texts of the remaining potentially eligible literatures were further assessed. Bibliographical characteristics of all of the eligible ME studies, including both searched by ourselves and references from the previously published systematic reviews [15, 16], were extracted using a self-developed form based on the previous systematic review [15]. The data extraction form has been piloted and refined among a sample of five ME studies. The study selection and data extraction were conducted by two trained researchers (HW, JL, WJ, YY, LQ and YC) in duplication. Any disagreement was discussed for consensus or consulted a senior researcher (IXYW). The following information was extracted from each ME study (Additional file 2: Appendix 2):

General characteristics of ME studies: year of publication; type of publication (journal article; agency report); involvement of epidemiologists/statisticians (referred to the definition reported by Delgado-Rodriguez et al. [27]); funding sources (public; private); type of intervention (pharmacology; non-pharmacology); medical conditions classified with the International Classification of Diseases 11th version (ICD-11); trial-level characteristics evaluated: some trial-level characteristics that included in the Cochrane RoB tool (e.g., sequence generation and allocation concealment), and others like sample size (larger sample, smaller sample) and number of centers (multicenter, single-center). Besides the above-mentioned pre-specified characteristics, we also included additional trial-level characteristics as post-hoc ones [e.g., publication language (English language, language other than English) and study design (parallel group, cross-over)] for the purpose of comprehensiveness.; type of outcome measure (binary; continuous; time-to-event); data sources for ME (collected meta-analyses, or trials, or previous ME studies);

Characteristics of the collections of meta-analysis: data sources (Cochrane review; non-Cochrane review); Page 3 of 17

type of meta-analysis (aggregated data; individual participant data; network meta-analysis); management of overlapping meta-analyses; minimum number of trials per meta-analysis; criteria of selecting one meta-analysis from systematic review including more than one metaanalysis; data extraction sources (individual trial and/or systematic review);

Characteristic of quantitative analyses: statistical methods; methods used to account for clustering of trials within meta-analyses and to adjust meta-confounders; information related to heterogeneity and whether reported the direction of interpreting the results (e.g., stated that ratio of odds ratio (ROR) < 1 showed larger treatment effect estimates for trials with smaller sample size, as compared with larger sample size).

#### Methodological quality assessment

To the best of our knowledge, there was no published tool specifically for evaluating the methodological quality of ME study. Hence, we used a self-developed criterion consisting of 16 items based on the AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews-2) [28] and the criteria used in a related systematic review published by Dechartres and colleagues [15]. Inclusion of these 16 items was based on consensus among all co-authors, with five items derived from AMSTAR 2 [28] and the remaining 11 items from Dechartres and colleagues' criteria (Additional file 3: Appendix 3) [15]. Pairs of trained researchers (HW, JL and YL) independently assessed the methodological quality of included ME studies [15, 16]. Discrepancies were resolved by discussion or consulting a senior researcher (IXYW) when they persisted.

#### Data analysis


All the results were narratively summarized and presented. Frequency (%) with their corresponding 95% confidence interval (CI) was used to summarize binary outcome, while median and interguartile or range for continuous outcome. Differences in treatment effect estimates were measured with ratio of effect size (e.g., ROR) for binary outcome and differences in standardized mean difference (SMD) for continuous outcome. Differences in treatment effect estimates were re-calculated to ensure a ratio of effect size less than 1 or a difference in SMD less than 0 reveal larger treatment effect estimates for trials with high or unclear risk of bias, or for trials with the second element (e.g., larger sample versus smaller sample, smaller sample was regarded as the second element). Associations between treatment effect estimates and trial-level characteristics were presented with forest plots. Similar to the previous systematic review [15], we did not combine the results from different ME studies instead of presenting them by forest plots due to the potential overlaps among ME studies. Results of subgroup analyses based on trial-level characteristics (e.g., type of outcome) or meta-analysis-level characteristics (e.g., type of review) were presented when available. All data analyses were conducted using R 3.6.1 (http:// www.R-project.org, the R Foundation for Statistical Computing, Vienna, Austria).

#### Results

Overall, 2705 citations were identified based on electronic databases search and reference lists checking. After excluding duplications, the remaining 1983 records were screened by their titles and abstracts. Accordingly, 131 went through full text assessments, with 80 ME studies (Additional file 4: Appendix 4) being included, and the remaining 51 being excluded with reasons (Additional file 5: Appendix 5). Figure 1 describes the results of literature search and process of literature selection.

## Bibliographical characteristics General characteristics

The 80 ME studies were published between 1995 and 2020 (median: 2013), with 25/80 (31%) being published after 2015 (the time of the last systematic review published) (Additional file 6: Appendix 6). Most ME studies were published as journal articles (76/80, 95%). Among them, 26/80 (32%) were published in general journals and 50/80 (62%) were published in medical specialty journals, including 26/80 (32%) in epidemiology/biostatistics journals. Moreover, 56/77 (73%) ME



studies involved at least one epidemiologist/statistician. Among the 64 ME studies that provided funding information, only two (2/64, 3%) received funding from private sources, 48/64 (75%) from public sources while the remaining 14 (14/64, 22%) did not receive any funding support (Table 1).

Most (51/62, 82%) ME studies assessed both pharmacological and non-pharmacological interventions. Binary outcomes were included in 60/80 (75%) ME studies, while time-to-event outcomes were included in only 5/80 (6%). Two thirds (48/72, 67%) ME studies covered various medical areas, followed by diseases of the digestive

Table 1 General characteristics of the 80 included meta-epidemiological (ME) studies<sup>a</sup>

General characteristics	No. of ME study <sup>b</sup>	% (95% Cl)
Median publication year, range	2013	1995–2020
Type of publication		
Journal article	76	95 (90 to 100)
Agency report	4	5 (0 to 10)
Journal articles		
General journal	26	32 (22 to 43)
Medical specialty journal	50	62 (52 to 73)
Epidemiology/biostatistics	26	32 (22 to 43)
Involvement of epidemiologists/statisticians <sup>c</sup>	56/77	73 (63 to 83)
Funding sources <sup>c</sup>		
Public	48/64	75 (64 to 86)
Private	2/64	3 (0 to 8)
None	14/64	22 (12 to 32)
Type of intervention <sup><math>c</math></sup>		
Pharmacological intervention	5/62	8 (1 to 15)
Non-pharmacological intervention	6/62	10 (2 to 17)
Both	51/62	82 (72 to 92)
Medical conditions <sup>c</sup>		
Various medical areas	48/72	67 (56 to 78)
Diseases of the digestive system	9/72	12 (5 to 20)
Pregnancy, childbirth or the puerperium	5/72	7 (1 to 13)
Diseases of the musculoskeletal system or connective tissue	5/72	7 (1 to 13)
Others <sup>e</sup>	5/72	7 (1 to 13)
Top five trial-level characteristics evaluated		
Allocation concealment	30	38 (27 to 48)
Sequence generation	24	30 (20 to 40)
Double blinding <sup>d</sup>	19	24 (14 to 33)
Blinding of outcome assessors	18	22 (13 to 32)
Blinding of participants	13	16 (8 to 24)
Type of outcome measure <sup>f</sup>		
Binary	60	75 (65 to 85)
Continuous	37	46 (35 to 57)
Time-to-event	5	6 (1 to 12)
Type of study design for literature search		
Collection of meta-analyses	63	79 (70 to 88)
Collection of trials	11	14 (6 to 22)
Combination of previously published ME studies	6	8 (2 to 13)
ME studies quantitatively synthesized a difference of treatment effect	68	85 (77 to 93)

<sup>a</sup> Values are numbers of ME studies, percentage (95% confidence interval) unless stated otherwise. <sup>b</sup>Denominators are 80 unless stated otherwise. <sup>c</sup>Denominators are not equal to 80 as some ME studies did not report relate information

<sup>d</sup> Described as double-blinding or  $\geq$  2 key groups (participants, personnel, outcome assessors) were blinded. <sup>e</sup>Others includes neoplasms (2, 2.8%), mental,

behavioural or neurodevelopmental disorders (1, 1.4%), diseases of the nervous system (1, 1.4%), and symptoms, signs or clinical findings, not elsewhere classified (1, 1.4%). <sup>f</sup>Total number was over 80, due to more than one type of outcome measure was used in some ME studies

system (9/72, 12%), pregnancy, childbirth, or the puerperium (5/72, 7%), and diseases of the musculoskeletal system or connective tissue (5/72, 7%) (Table 1, Additional file 7: Appendix 7). The most frequently evaluated trial-level characteristic was allocation concealment (30/80, 38%), followed with sequence generation (24/80, 30%), double blinding (19/80, 24%), blinding of outcome assessors (18/80, 22%), and blinding of participants (13/80, 16%). Additional file 8: Appendix 8 shows detailed trial-level characteristics evaluated in each ME study.

#### Details of the collected meta-analyses among the ME studies

Most (63/80, 79%) ME studies were based on data collected from meta-analyses, only 11/80 (14%) utilized data collected from trials and 6/80 (8%) directly collected data from previously published ME studies (Table 1). Among the 63 ME studies based on data from meta-analyses, 58 reported data sources, including 28/58 (48%) only considering Cochrane review, 3/58 (5%) only considering non-Cochrane review and 27/58 (47%) considering both. Most (58/63, 92%) ME studies were based on aggregated data meta-analyses, with the remaining five considered other type of meta-analyses, including both aggregated data and individual participant data (3/63, 5%), individual participant data only (1/63, 2%) and network of aggregated data only (1/63, 2%). Thirty-five (35/63, 56%) ME studies explicitly managed overlapping meta-analyses, whereas 28/63 (44%) did not report related information. The minimum number of trials included per meta-analysis ranged from one to ten, while 26/63 (41%) ME studies did not provide this information. When the included systematic review had more than one meta-analysis, fortyfour (44/63, 70%) ME studies selected one meta-analysis from each systematic review, based on multiple criteria (20/44, 45%) or the primary outcome (10/44, 23%). Four ME studies (4/63, 6%) included all meta-analyses reported in systematic reviews without selection, while the remaining 15/63 (24%) did not mention relevant information (Table 2).

#### Details of quantitative analyses among the ME studies

Most (68/80, 85%) ME studies quantitatively synthesized the difference of treatment effect estimates (Table 1). The most commonly used method for combining results was two-step approach (within-meta-analysis comparison and then combination) (43/68, 63%). Clustering of trials within a meta-analysis was accounted in 53 of the 61 (87%) ME studies based on data from meta-analyses. More than 70% ME studies assessed the heterogeneity during data synthesis (59/68, 87%), adjusted meta-confounders (54/68, 79%), and used random effect models to take into account variability across meta-analyses/trials (43/61, 70%). Sixty (60/68, 88%) ME studies clearly reported the direction of interpreting the results, while the remaining 8/68 (12%) did not provide this information. Forty-eight (48/68, 71%) ME studies conducted subgroup analyses either based on trial-level characteristics or meta-analysis-level characteristics (Table 3). Additional file 9: Appendix 9 presents detailed information on the subgroup analyses of the included ME studies.

#### Methodological quality

The included ME studies generally performed well in three items, with at least 90% compliance rates. These included giving a clear description of inclusion criteria and reasons for exclusion (74/80, 92%), reporting information related to conflicts of interest and funding supports (74/80, 92%), and providing a clear definition of trial characteristics evaluated in ME studies (72/80, 90%). On the other hand, less than one third ME studies fulfilled the following three methodological criteria: assessing the methodological quality of the included studies (26/80, 33%), publishing a protocol developed prior to the conduct of the ME study (23/80, 29%), and providing a list of excluded studies with justifications (12/80, 15%) (Table 4).

## Impact of trial-level characteristics on treatment effect estimates

## **Binary outcomes**

Eleven out of 14 (11/14) ME studies indicated that trials with high or unclear risk of bias for sequence generation showed associations with larger treatment effect estimates, three of which found such associations statistically significant. Fourteen out of 18 (14/18) ME studies showed trials with high of unclear risk of bias on allocation concealment were associated with larger treatment effect estimates (11 found statistically significant associations). Ten out of 15 (10/15) ME studies showed that trials with high or unclear risk of bias on double blinding related to larger treatment effect estimates, of which such associations in five ME studies were statistically significant. Aforementioned associations were also observed when blinding was considered separately as blinding of participants (5/5 ME studies), blinding of personnel (1/4 ME studies) and blinding of outcome assessors (4/8 ME studies). As for blinding of outcome assessor, one out of four ME studies showed statistically significant association) (Fig. 2).

All of (5/5) ME studies showed that trials with smaller sample size had an association with larger treatment effect estimates than that of trials with larger sample size, four of which found statistically significant associations. Above-mentioned significant association was especially seen in one ME study [11] regardless of the definition of smaller and larger sample size (e.g., Q1 Table 2 Characteristics of 63 meta-epidemiological (ME) studies based on collection of meta-analyses<sup>a</sup>

Characteristics	No. of ME study <sup>b</sup>	% (95% CI)	
 Data sources <sup>⊂</sup>			
Cochrane review only	28/58	48 (35 to 62)	
Non-Cochrane review only	3/58	5 (0 to 11)	
Non-Cochrane review published in "high impact factor" journals	1/58	2 (0 to 5)	
Both Cochrane and non-Cochrane review	27/58	47 (33 to 60)	
Non-Cochrane review published in "high impact factor" journals and Cochrane	8/58	14 (5 to 23)	
Type of meta-analyses			
Aggregated data only	58	92 (85 to 99)	
Aggregated and individual participant data	3	5 (0 to 10)	
Individual participant data only	1	2 (0 to 5)	
Network of aggregated data only	1	2 (0 to 5)	
Management of overlapping meta-analyses	35	56 (43 to 68)	
Reported minimum No. of trials included in each meta-analysis	37	59 (46 to 71)	
Minimum No. of trials included in meta-analysis, median (Q1, Q3) <sup>d</sup> , range $^{\rm e}$	3 (2,4)	1 to 10	
Criteria of selecting one meta-analysis within each systematic review			
Primary outcome	10/44	23 (10 to 36)	
Largest number of studies	4/44	9 (0 to 18)	
Objective	3/44	7 (0 to 15)	
First outcome	2/44	4 (0 to 11)	
Others <sup>g</sup>	5/44	11 (2 to 21)	
More than one method	20/44	45 (30 to 61)	
Data extraction sources <sup><math>c</math></sup>			
From individual trial	19/60	32 (20 to 44)	
From meta-analysis	8/60	13 (4 to 22)	
Both	33/60	55 (42 to 68)	

<sup>a</sup> Values are numbers of ME studies, percentage (95% confidence interval) unless stated otherwise. <sup>b</sup>Denominators are 63, unless stated otherwise. <sup>c</sup>Denominators are not equal to 63 as some ME studies did not report relate information. <sup>d</sup>Q1, Quartile 1. <sup>e</sup>Among 63 ME studies, 26 ME studies did not report minimum number of trials included in meta-analysis. <sup>f</sup>Denominator is 44, as four ME studies included all meta-analysis within each systematic review while 15 ME studies did not report relate information. <sup>g</sup>Others includes selection methods of first outcome statistically significant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most lity (1, 2.1%), most clinically relevant (1, 2.1%), most

versus Q4, < 50 versus  $\geq$  50) (Fig. 2, Additional file 10: Appendix 10). Two out of two (2/2) ME studies showed larger treatment effect estimates for early stopping trials, and such association was found statistically significant in 1/2 ME study. Inconsistencies in direction of point estimation on ratio of effect size were observed among the ME studies for trials with high or unclear risk of bias in incomplete outcome data (4 ME studies) and selective outcome reporting (3 ME studies). All of three (3/3) ME studies showed that published trials, compared with grey literature, produced larger treatment effect estimates, with 2/3 ME studies showing statistically significant association. Four out of five (4/5)ME studies showed larger treatment effect estimates for trials published in language other than English, two of which found it statistically significant. Inconsistent results were seen in non-Medline indexed trials versus Medline indexed trials as well, with two (2/4) ME studies showing lower treatment effect estimates for non-Medline indexed trials, while remained two (2/4) indicating larger.

Results from four out of five (4/5) ME studies revealed that single-center trials were associated with larger treatment effect estimates than that of multi-center trials, so did cross over trials than that of parallel trials (2/2 ME studies). Such associations were found statistically significant in 2/4 and 1/2 ME studies, respectively. Two out of four (2/4) ME studies found that trials without conducting intention to treat analysis showed larger treatment effect estimates, one of which found it statistically significant. Nonetheless, no statistical association were found between trials with baseline imbalance (3 ME studies), existence of competing interests (2 ME studies) and industry funding (3 ME studies) and treatment effect estimates (Fig. 2).

One ME study [29] demonstrated that overall trials showed significantly much lower treatment effect Table 3 Characteristics of 68 meta-epidemiological (ME) studies quantitatively synthesized a difference of treatment effect estimates<sup>a</sup>

Statistical analysis	No. of ME study <sup>b</sup>	% (95% CI)
Which model the ME study used to combine?		
Two-step approach: within-meta-analysis comparison and combination	43	63 (52 to 75)
Logistic regression	7	10 (3 to 18)
Two-step approach: within-trial comparison and combination	5	7 (1 to 14)
Bayesian multilevel model	5	7 (1 to 14)
Meta-regression	3	4 (0 to 9)
More than one model <sup>c</sup>	5	7 (1 to 14)
Accounted for clustering of trials within meta-analysis <sup>d</sup>	53/61	87 (78 to 96)
Used random effect models to account for variability across meta-analyses/trials		
Yes <sup>e</sup>	43/61	70 (59 to 82)
No <sup>e</sup>	18/61	30 (18 to 41)
Adjusted meta-confounders	54	79 (70 to 89)
Based on subgroup analysis solely <sup>e</sup>	32/54	59 (46 to 73)
Based on multiple variable analysis solely <sup>e</sup>	6/54	11 (2 to 20)
Both <sup>e</sup>	16/54	30 (17 to 42)
lf yes, as main analysis <sup>e</sup>	21/54	39 (26 to 52)
Assessed the heterogeneity during analysis	59	87 (78 to 95)
Based on qualitative domain solely (chi-square test) <sup>e</sup>	4/59	7 (0 to 13)
Based on quantitative domain solely (I <sup>2</sup> , $\tau^2$ , $\phi^2$ , F test) <sup>e</sup>	20/59	34 (22 to 46)
Both <sup>e</sup>	35/59	59 (46 to 72)
Whether the author clearly reported the direction of interpretation of results		
Yes	60	88 (80 to 96)
No	8	12 (4 to 20)
Subgroup analyses performed	48	71 (60 to 82)
Based on trial-level characteristics <sup>e</sup>	30/48	62 (48 to 77)
Based on meta-analysis-level characteristics <sup>e</sup>	1/48	2 (0 to 6)
Both <sup>e</sup>	17/48	35 (21 to 50)

<sup>a</sup> Values are numbers of ME studies, percentage (95% confidence interval) unless stated otherwise. <sup>b</sup>Denominators are 68 unless stated otherwise. <sup>c</sup>More than one model includes methods of using both two-step approach and multilevel model (3,4.9%), using both two-step approach and logistic regression (1,1.6%), and using both two-step approach, logistic regression and multilevel model (1,1.6%). <sup>d</sup>Denominator is 61, as seven ME studies based on collection of trials are not applicable to this item. <sup>e</sup>Denominator are not equal to 68, as some ME studies did not report related information

estimates than that of first trial (ratio of effect size: 2.67, 95% CI: 2.12–3.37), although the remaining ME study [30] did not find such association (ratio of effect size: 1.03, 95% CI: 0.98–1.08). Several other trial-level characteristics including sufficient follow-up, placebo control and statistician involvement, among others have been investigated as well, with no significant associations being found (Additional file 10: Appendix 10).

#### **Continuous outcomes**

Three out of six (3/6) ME studies reported the association between trials with high or unclear risk of bias on sequence generation and larger treatment effect estimates (1/3 ME study showing statistically significant association). Four out of six (4/6) ME studies showed trials with high or unclear risk of bias on allocation concealment related to larger treatment effect estimates, of which one ME study found it statistically significant. Inconsistencies in direction of point estimation on difference of effect size were seen among the ME studies when blinding was separately considered as three independent parties, including blinding of participants (8 ME studies), blinding of personnel (4 ME studies) and blinding of outcome assessors (7 ME studies). Such inconsistencies were removed when the three parties were considered at the same time as double blinding, with three out of four (3/4) ME studies showed larger treatment effect estimates for trials with high or unclear risk of bias (1/3 ME study found such association statistically significant) (Fig. 3).

Three ME studies consistently found that smaller sample size (or inadequate powered) trials were related to larger treatment effect estimates. One out of two (1/2) ME studies reported that trials with drop outs were associated with lower treatment effect estimates (Fig. 3), while the other ME study showed opposite direction. Additionally, single-center trials (1 ME study), individual

#### Table 4 Methodological quality of the sampled 80 meta-epidemiological (ME) studies

Methodological items	Yes		No	
	No. of ME studies	% (95% CI)	No. of ME studies	% (95% Cl)
M1. Did the author state that they had published a protocol prior to the conduct of the ME study?	23	29 (19 to 39)	57	71 (61 to 81)
M2. Did the author use a comprehensive literature search strategy?	46	58 (46 to 69)	34	42 (31 to 54)
M3. Did the author give a clear description of inclusion criteria and reasons for exclusion?	74	92 (87 to 98)	6	8 (2 to 13)
M4. Whether selection process was reported?	69	86 (78 to 94)	11	14 (6 to 22)
M5. Did the author perform selection process in duplicate?	40	50 (39 to 61)	40	50 (39 to 61)
M6. Did the author perform data extraction in duplicate? <sup>a</sup>	52	88 (79 to 97)	7	12 (3 to 21)
M7. Did the author provide a list of excluded studies and justify the exclusions? <sup>b</sup>	12	15 (7 to 23)	65	81 (72 to 90)
M8. Did the author evaluate the heterogeneity between included meta-analyses or trials or ME studies? $^{\rm c}$	59	87 (78 to 95)	9	13 (5 to 22)
M8i. Did the author perform an investigation of sources of any heterogeneity? <sup>c</sup>	35	83 (72 to 95)	7	17 (5 to 28)
M9. Whether analysis was adjusted on meta-confounders for ME studies estimating a combined difference of treatment effect? <sup>c</sup>	54	79 (70 to 89)	14	21 (11 to 30)
M10. Whether clustering of trials within meta- analyses was taken into account for ME studies based on a collection of meta-analyses or previous ME studies? <sup>c</sup>	53	87 (78 to 96)	8	13 (4 to 22)
M11. Did the author report any potential sources of conflict of interest, including any funding they received for conducting the ME study?	74	92 (86 to 98)	6	8 (2 to 14)
M12. Whether checking experimental and control arms were reported?	40	51 (39 to 62)	40	49 (38 to 61)
M13. Whether the author reclassified of outcomes reported to have the same sense of interpreta- tion?	56	71 (61 to 81)	24	29 (19 to 39)
M14. Did the author give a clear definition of trial characteristics evaluated in ME studies?	72	90 (83 to 97)	8	10 (3 to 17)
M15. Did the author assess the trial characteristics evaluated in duplicate?	64	80 (71 to 89)	16	20 (11 to 29)
M16. Did the author assess the methodological quality of the included ME studies or meta-analyses or trials?	26	33 (22 to 44)	54	67 (56 to 78)

<sup>a</sup> Denominator is 59 as 21 ME studies did not report related information. Among 52 ME studies perform data extraction in duplicate, 34 (57.6%) ME studies was fully or partly in duplicate, 6 (10.2%) was checked by a second reviewer, 3 (5.1%) mentioned contact to authors and 9 (15.3%) used more than one aforementioned method. <sup>b</sup>Three ME studies provided a list of excluded studies but without reasons. <sup>c</sup>Denominator is not equal to 80, as some ME studies were not applicable to this item


RCT (versus cluster RCT) (1 ME study) and trials with no protocol registration (1 ME study) showed significant associations with larger treatment effect estimates. Most trial characteristics did not show any significant associations with treatment effect estimates in continuous outcomes, including early stopping (1 ME study), incomplete outcome reporting (1 ME study), selective outcome reporting (1 ME study), intention to treat analysis (2 ME studies), baseline imbalance (4 ME studies) and industry funded trials (1 ME study), among others (Fig. 3).

#### Subgroup analyses

For binary outcomes, larger treatment effect estimates were observed in trials with high or unclear risk of bias on allocation concealment (6/6 ME studies for subjective outcome and 6/10 ME studies for objective outcome) and double blinding (4/5 ME studies for subjective outcome and 6/8 ME studies for objective outcome). The significant associations between high or unclear risk of bias and larger treatment effect estimates were much more frequently observed among subjective outcomes than that of objective outcomes [allocation concealment (5/6 versus 1/10 ME studies) and double blinding (4/5 versus 2/8 ME studies)] (Fig. 4-a). For continuous outcomes, trials with high or unclear risk of bias on allocation concealment (2/3 and 1/3 ME studies for subjective outcome and objective outcome, respectively) and double blinding (3/3 and 2/3 ME studies for subjective outcome and objective outcome, respectively) related to larger treatment effect estimates. However, 1/3 ME study found that abovementioned associations were statistically significant only in the subjective outcome (Fig. 4-b).

For both binary and continuous outcomes, larger treatment effect estimates for trials with high or unclear risk of bias on blinding of outcome assessors were only observed in trials using single observer for non-blinded assessment (compared with trials using multiple observer consensus for non-blinded assessment) and trials with industry funding (trials with non-commercial funding) (Fig. 4).

For binary outcomes, larger treatment effect estimates for trials published in language other than English



	Trial-level characteristics	Study Van Tulder,2009		No. of MA (RCTs)*		0.02(-0.12 to 0.16)
	Sequence generation	Hempel,2012 Hartling,2014		12 (165) 17 (287)		0.01(-0.15 to 0.17) -0.07(-0.22 to 0.08)
	bequence generation	Armijo-Olivo,2015 Papageorgiou,2015		22 (257) 25 (75)		0.02(-0.12 to 0.15) -0.01(-0.26 to 0.25)
		Saltaji,2018(a)		52 (467)		-0.13(-0.25 to -0.01)
		Nuesch,2009 Van Tulder,2009(a)		14 (158) NR (216)		-0.15(-0.31 to 0.02) -0.08(-0.23 to 0.07)
	Allocation concealment	Hempel,2012 Hartling,2014 Armiio-Olivo.2015		12 (165) 17 (287) 17 (198)		-0.05(-0.22 to 0.11) 0.09(-0.15 to 0.33) 0.12(-0.06 to 0.30)
		Saltaji,2018(a) Double blinding		39 (345)		-0.15(-0.27 to -0.02)
		Hartling,2014 Saltaji,2018(b)		17 (287) 28 (294)		0.00(-0.09 to 0.09) -0.09(-0.22 to 0.05)
		Blinding of patients Nuesch,2009(a) Van Tulder,2009		10 (122) NR (216)	<b>.</b>	-0.15(-0.39 to 0.09) -0.03(-0.18 to 0.11)
		Hempel,2012 Hrobiartsson.2014(a	a)	12 (165)		
		Armijo-Olivo,2016 Bolvig,2018	~,	NR (12) ++		0.12(-0.06 to 0.30) -0.15(-0.29 to -0.01)
		Saltaji,2018(b) Armijo-Olivo,2020		28 (275) 4 ME studies (706)	<del></del>	-0.12(-0.23 to -0.00) -0.19(-0.48 to 0.10)
		Blinding of health pr Van Tulder,2009	ofessionals	NR (216)		-0.10(-0.26 to 0.06) 0.19( 0.03 to 0.35)
		Hempel,2012 Armiic=Olivo 2016		NR (216) 12 (165) 7 (113)	<b>_</b>	-0.10(-0.38 to 0.17)
	Blinding	Saltaji,2018(b)		18 (408)		-0.02(-0.09 to 0.04)
		Blinding of outcome Van Tulder,2009 Hempel,2012	444435013	NR (216) 12 (165)	<u> </u>	-0.10(-0.25 to 0.04) 0.06(-0.28 to 0.41)
		Hrobjartsson,2013 Hartling,2014		NR (16) 17 (287)		-0.23(-0.40 to -0.06 -0.00(-0.11 to 0.11)
		Armijo-Olivo,2016 Saltaji,2018(b)		NR (165) 44 (408)	<del></del> +	0.07(-0.08 to 0.22) -0.06(-0.18 to 0.06)
		Armijo-Olivo,2020		4 ME studies (478)		-0.10(-0.31 to 0.11)
		Blinding of both pati Saltaji,2018(b) Blinding of patients		19 (224)		-0.19(-0.32 to -0.06
		Saltaii.2018(b)	, health professionals and outcome assessor alvst	10 (151)	<b></b>	-0.14(-0.25 to -0.03
		Blinding of data ana Armijo-Olivo,2016 Overall adequacy or	f blinding	6 (89)		-0.04(-0.27 to 0.18)
		Armijo-Olivo,2016 Methods of blinding	(appropriate/inappropriate or unclear)	16 (182)	_ <del></del>	0.08(-0.12 to 0.28)
		Saltaji,2018(b) Drop out		40 (NR)		-0.06(-0.18 to 0.06)
		Van Tulder,2009 Hempel,2012		NR (216) 12 (165)		-0.13(-0.29 to 0.02) 0.15( 0.01 to 0.29)
	Missing data	Incomplete outcom Hartling,2014	e data	17 (287)		-0.09(-0.26 to 0.07)
		Exclusion of particip Nuesch,2009(b)	pants	14 (167)		-0.13(-0.29 to 0.04)
h	Selective outcome reporting MA, meta-analyses; RCT, rando "Values are numbers of MA (RC	mized controlled trial; ME, mel	ta-epidemiological; NR, not reported; CI, confidenc			-0.06(-0.15 to 0.04) 0.4 0.6 th righ / unclear risk of bias w lower treatment effect
b	MA, meta-analyses; RCT, rando	mized controlled trial; ME, me (Ts) unless stated otherwise.	ta-epidemiological; NR, not reported; Cl, confidenc	-0.6 Trials with high	/ unclear risk of bias Difference Trials w	0.4 0.6 th high / unclear risk of bias w lower treatment effect
2	MA, meta-analyses; RCT, rando. "Values are numbers of MA (RC <b>Tria⊢level characteristi</b>	mized controlled trial; ME, met Ts) unless stated otherwise.	tudy	n -0.6 e interval Trisis with high show larger No. of MA (RCTs)	/ unclear risk of bias Difference Trials w	0.6 h high / unclear risk of bias w lower treatment effect Difference of effect size(9
D	MA, meta-analyses; RCT, rando "Values are numbers of MA (RC	mized controlled bial; ME, me Ts) unless stated otherwise. Ics St atients) Ne		r –0.6 Triats with high , e interval Show larger	/ unclear risk of bias Difference Trials w	0.4 0.6 h high runclear risk of bias w lower treatment effect Difference of effect size(s -0.21(-0.34 to -C
C	MA, meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial-size(number of pa	enized controlled tiisi .ME, me T's) unless stated otherwise. Ics St atients) Nt mple) Bo	<b>tudy</b> uesch.2010(≥100 vs <100 per anm) alvig.2018(≥128 vs <128)	-0.6 Triais with high show larger No. of MA (RCTs) 13 (153) 20 (126)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear risk of bias w lower treatment effect Difference of effect size(1 -0.21(-0.34 to -0 -0.29(-0.42 to -0
0	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa	Imized controlled trial; ME, met Traj unless stated otherwise. International control otherwise statients) No mple) Brook Variable Variable	<b>tudy</b> uesch,2010(≥100 vs <100 per am) Jolvíg.2018(≥128 vs <128) an Tulder,2009	•••6           ••06           Trials with high.           show larger           13 (153)           20 (126)           NR (216)	/ unclear risk of bias Difference Trials w	0.0.0.0 h high / unclear risk of bias w bower treatment effect Difference of effect size( -0.21(-0.34 to -( -0.29(-0.42 to -( -0.10(-0.24 to 0.1))))))))))))))))))))))))))))))))))))
ס	MA, meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial-size(number of pa	rmized controlled tisk, ME, me TTS jurdess stated otherwise. (cs St attents) Ni mple) B; Va otypes) Hit	<b>uudy</b> uesch.2010(≥100 vs <100 per arm) olvig.2018(≥128 vs <128) an Tulder,2009 empel.2012	Image: 100 minipage         Image: 100 minipage           No. of MA (RCTs)         Image: 100 minipage           13 (153)         20 (126)           NR (216)         12 (165)	/ unclear risk of bias Difference Trials w	0.0.0 h hgh / unclear risk of bias w jower treatment effect Difference of effect size( -0.21(-0.34 to -( -0.28(-0.42 to -( -0.10(-0.24 to 0) -0.09(-0.24 to 0)
ס	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa	rnized controlled tist, ME, Ind TS) untess stated otherwise. cs Statents) Ni mple) B V2 otyces) Hi	<b>tudy</b> uesch,2010(≥100 vs <100 per am) Jolvíg.2018(≥128 vs <128) an Tulder,2009	•••6           ••06           Trials with high.           show larger           13 (153)           20 (126)           NR (216)	/ unclear risk of bias Difference Trials w	0.4 0.6 In high / unclear risk of bias with over treatment effect Difference of effect size( -0.21(-0.34 to -( -0.29(-0.42 to -( -0.02(-0.24 to 0. -0.00(-0.24
)	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (n	rnized controlled tisk, ME, Inne TTO, untees stated otherwise. cs St stients) Nu mple) Bc Va Va Sz olytes) Hit Sz	tudy uesch.2010(≥100 vs <100 per amm) olvig.2018(≥128 vs <128) an Tulder,2009 empel.2012 antling.2014	usinterval         -0.6 -0.6 Trisis with high: show larger           No. of MA (RCTs)	/ unclear risk of bias Difference Trials w	0.4 0.5 http://urciaarrisk.of.bias bibwor treatment effect -0.21(-0.34 to -( -0.29(-0.42 to -0) -0.10(-0.24 to 0.0) -0.09(-0.42 to 0.0) -0.09(-0.42 to 0.0) -0.09(-0.28 to 0.0) -0.07(-0.28 to 0.0) -0.07(-0.28 to 0.0) -0.01(-0.12 to 0.0)
C	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa	rinzad confidentisti, ME: me rics Stated otherwise. ris unters stated otherwise. Statients) N. mple) Bc olyees) Hi Hi States olyees) Va sis (yes/no) Va	tudy uesch.2010(2100 vs <100 per anm) alv/g.2018(2128 vs <128) an Tulder,2009 empel.2012 artifuig.2014 attelij.2018(a)	No. of MA (RCTs)           13 (153)           20 (126)           12 (165)           17 (287)           32 (310)	/ unclear risk of bias Difference Trials w	0.4 0.5 http://urclear.risk.of.bias wit.bow? treatment effect -0.21(-0.34 to -1 -0.29(-0.42 to -0 -0.10(-0.24 to 0.1 -0.06(-0.24 to 0.1 -0.07(-0.28 to 0.1 -0.07(-0.28 to 0.1 -0.01(-0.12 to 0.1 -0.10(-0.24 to 0.1 -0.10(-0.24 to 0.1)
)	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (n	rnized confided bitk ME, Inne TTO, untress stated otherwise. cs St stients) Nu mple) Bc olyees) Ht Sz rsis (yes/no) Va Ht	uudy uesch.2010(≥100 vs <100 per arm) olvig.2018(≥128 vs <128) an Tulder,2009 empel.2012 artling.2014 altaji.2018(a) an Tulder,2009	No. of MA (RCTs)           13 (153)           20 (126)           13 (153)           20 (126)           NR (216)           12 (165)           17 (287)           32 (310)           NR (216)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear mix of bias withower treatment effect 0.21(-0.34 to -0 -0.28(-0.42 to -0 -0.28(-0.42 to -0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.01(-0.12 to 0.0 -0.01(-0.24 to 0.0 0.05(-0.10 to 0.2
2	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (n Intention to treat analy	minicad controlled trial; ME: mer Trib unbess stated otherwise. tatients) Nu mple) Br V2 olyges) He Hit Sis Sis Sis (yes/nc) V2 Hit Hit Sis	tudy uesch.2010(≥100 vs <100 per arm) okig.2018(≥128 vs <128) an Tulder,2009 artling.2014 altaji.2018(a) an Tulder.2009 empel.2012	-0.6           Triais with high, show larger           No. of MA (RCTs)           13 (153)           20 (126)           NR (216)           12 (165)           NR (216)           12 (165)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high unclear risk of bias withow treatment effect -0.21(-0.34 to -0 -0.29(-0.42 to -0 -0.10(-0.24 to 0.0 -0.09(-0.42 to 0.0 -0.09(-0.24 to 0.0 -0.09(-0.24 to 0.0 -0.01(-0.12 to 0.0 -0.01(-0.24 to 0.0 0.05(-0.10 to 0.2 0.09(-0.05 to 0.2
)	MA. mete-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (n Intention to treat analy Whether co-interventio	inizad controlled visit, ME, Inne TTO, unitess stated otherwise. attients) Ni attients) Ri attients) Ri attients) Ri visit (yes/no) Hi si si si acceptable? Visit	tudy           uesch.2010(≥100 vs <100 per arm)	No. of MA (RCTs)           13 (153)           20 (126)           17 (287)           32 (310)           NR (216)           12 (165)           12 (165)           NR (216)           NR (216)           NR (216)           NR (216)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear risk of bias wit lower treatment effect -0.21(-0.34 to -( -0.29(-0.42 to -( -0.09(-0.42 to 0) -0.00(-0.24 to 0) -0.00(-0.24 to 0) -0.00(-0.24 to 0) -0.00(-0.24 to 0) -0.01(-0.24 to 0) -0.01(-0.24 to 0) 0.05(-0.10 to 0.2 0.05(-0.15 to 0.2 -0.01(-0.15 to 0.2) -0.01(-0.15 to 0.2)
כ	MA meta-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial-size(number of pa (large sample/small sa Baseline imbalance (na Intention to treat analy Whether co-interventio (nalyes)	inizad controlled visit, ME, Inne TTO, unitess stated otherwise. attients) Ni attients) Ri attients) Ri attients) Ri visit (yes/no) Hi si si si acceptable? Visit	tudy           uesch.2010(≥100 vs <100 per arm)	no. of MA (RCTs)           13 (153)           20 (126)           17 (1287)           32 (310)           NR (216)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear mix of bias withower treatment effect -0.21(-0.34 to -0 -0.29(-0.42 to -0 -0.09(-0.42 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 0.05(-0.15 to 0.2 0.09(-0.51 to 0.2 -0.01(-0.15 to 0.1 -0.01(-0.15 to 0.1)
)	MA. meta-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (n Intention to treat analy Whether co-interventio (nolyes) Whether compliance is	cs SI To untees stated otherwise. cs SI stients) NU mple) B vi olyces) Hi sis (yes/no) Vi s acceptable? Vi me assessment Vi	tudy           uesch.2010(>100 vs <100 per arm)	No. of MA (RCTs)           13 (153)           20 (126)           17 (1287)           32 (310)           NR (216)           12 (165)	/ unclear risk of bias Difference Trials w	Difference of effect size(9 Difference of effect size(9 -0.21(-0.34 to -0 -0.22(-0.42 to -0 -0.22(-0.42 to -0 -0.10(-0.24 to 0.0 -0.09(-0.24 to 0.0 -0.09(-0.24 to 0.0 -0.01(-0.12 to 0.0 0.05(-0.10 to 0.2 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 -0.01(-0.15 to 0.1 0.02(-0.12 to 0.1 -0.17(-0.43 to 0.1 -0.17(-0.15) -0.17(-
)	MA. mete-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (no Intention to treat analy Whether co-interventio (no/yes) Whether compliance is (yes/no)	cs SI To untees stated otherwise. cs SI stients) NU mple) B vi olyces) Hi sis (yes/no) Vi s acceptable? Vi me assessment Vi	uudy uesch.2010(≥100 vs <100 per arm) olvig.2018(≥128 vs <128) an Tulder,2009 empel.2012 antigi.2018(a) an Tulder,2009 empel.2012 an Tulder,2009 empel.2012	No. of MA (RCTs)           13 (153)           20 (126)           13 (153)           20 (126)           12 (165)           17 (287)           32 (310)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)	/ unclear risk of bias Difference Trials w	Difference of effect size(9 Difference of effect size(9 -0.21(-0.34 to -0 -0.22(-0.42 to -0 -0.22(-0.42 to -0 -0.10(-0.24 to 0.0 -0.09(-0.24 to 0.0 -0.09(-0.24 to 0.0 -0.01(-0.12 to 0.0 -0.01(-0.12 to 0.0 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 -0.01(-0.15 to 0.2 -0.01(-0.15 to 0.1
)	MA. mete-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial size(number of pr (large sample/small sa Baseline imbalance (no Intention to treat analy Whether co-interventio (no/yes) Whether compliance is (yes/no) Similartiming of outcom (yes/no) Adequately powered/p	imized controlled hisk, ME, me imized controlled hisk, ME, me is statients) NL mple) Bc olyes) HH Hi sis (yes/no) V2 yais (yes/no) V2 s acceptable? V2 Hi me assessment V2 Hi me assessment V2 Hi Hi me assessment V2 Hi Hi Hi Hi Hi Hi Hi Hi Hi Hi	uudy uesch.2010(≥100 vs <100 per arm) olvig.2018(≥128 vs <128) an Tulder,2009 empel.2012 antidig.2018(a) an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012	No. of MA (RCTs)           13 (153)           20 (126)           12 (165)           17 (287)           32 (310)           NR (216)           12 (165)           12 (165)	/ unclear risk of bias Difference Trials w	0.4 0.6 m high / unclear insk of blas wit lower treatment effect 2017(-0.24 to 0.1 -0.29(-0.42 to -1 -0.09(-0.24 to 0.1 -0.09(-0.24 to 0.1 -0.07(-0.28 to 0.1 -0.07(-0.28 to 0.1 -0.07(-0.28 to 0.1 -0.07(-0.28 to 0.1 -0.07(-0.28 to 0.1 -0.07(-0.28 to 0.1 -0.09(-0.15 to 0.1 0.09(-0.15 to 0.1 0.02(-0.15 to 0.1 0.02(-0.15 to 0.1 0.02(-0.19 to 0.4 -0.17(-0.43 to 0.1 0.25(-0.19 to 0.4 0.10(0.08 to 0.1 0.10(0.08 to 0.1)
D	MA. mete-analyses; RCT, rando ™alues are numbers of MA (RC Trial-level characteristi Trial size(number of pa (large sample/small sa Baseline imbalance (n Intention to treat analy Whether co-interventio (nolyes) Whether compliance is (yes/no) Similartiming of outcoor (yes/no)	imized controlled hisk, ME, me imized controlled hisk, ME, me is statients) NL mple) Bc olyes) HH Hi sis (yes/no) V2 yais (yes/no) V2 s acceptable? V2 Hi me assessment V2 Hi me assessment V2 Hi Hi me assessment V2 Hi Hi Hi Hi Hi Hi Hi Hi Hi Hi	tudy           uesch,2010(≥100 vs <100 per am)	No. of MA (RCTs)           13 (153)           20 (126)           7/148 with high, above larger           8, 100 (126)           17 (287)           32 (210)           NR (216)           12 (165)	/ unclear risk of bias Difference Trials w	0.4 0.6 m high / undear ink of bias in high / undear ink of bias Difference of effect size(s -0.21(-0.34 to -0 -0.29(-0.42 to -0 -0.10(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.15 to 0.1 0.02(-0.15 to 0.1 0.02(-0.15 to 0.1 -0.17(-0.43 to 0.1 -0.25(-0.19 to 0.6 0.10(0.08 to 0.1)
ס	MA. mete-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial size(number of pr (large sample/small sa Baseline imbalance (no Intention to treat analy Whether co-interventio (no/yes) Whether compliance is (yes/no) Similartiming of outcom (yes/no) Adequately powered/p	rinized controlled visit, ME, Inne To, Unitess stated otherwise. Statients) NU statients) RC Tolytes) RC rais (yes/no) RC rais (yes/	uudy uesch.2010(≥100 vs <100 per arm) olvig.2018(≥128 vs <128) an Tulder,2009 empel.2012 antidig.2018(a) an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012	No. of MA (RCTs)           13 (153)           20 (126)           12 (165)           17 (287)           32 (310)           NR (216)           12 (165)           12 (165)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear risk of bias wit lower treatment effect 0.221(-0.34 to -( -0.22(-0.42 to 0.1 -0.02(-0.42 to 0.1 -0.00(-0.24 to 0.1 -0.00(-0.24 to 0.1 -0.00(-0.24 to 0.1 -0.00(-0.24 to 0.1 -0.01(-0.24 to 0.1 -0.01(-0.24 to 0.1 -0.01(-0.24 to 0.1 0.05(-0.15 to 0.2 0.09(-0.05 to 0.2 0.09(-0.05 to 0.2 0.02(-0.12 to 0.1 -0.01(-0.15 to 0.1 0.02(-0.12 to 0.1 -0.17(-0.43 to 0.1 -0.17(-0.49 to 0.1) -0.17(-0.49 to 0.1) -0.17(-0.19) -0.17(-0.19) -0.17(-0.19) -0.1
ס	MA. meta-analyses; RCT. rando "Values are numbers of MA (RC Trial-level characteristic Trial-size(number of pa (large sample/small sa (large sample/small sa large sample/small sa Intention to treat analy Whether co-interventio (nolyes) Whether compliance is (yes/no) Similartiming of outcom (yes/no) Adequately powered/p Early stopping (nolyes) Other sources of bias (domain in Cochrane ri	inized conducts tisk, ME, Infe inized conducts tisk dotherwise. Its unterest stated otherwise. Statients) NU mple) BC V4 HC Si sis (yes/mo) V4 HC s acceptable? V4 HC me assessment V4 HC Si source <50% T. Si Si HC HC HC HC HC HC HC HC HC HC	tudy           uesch.2010(≥100 vs <100 per arm)	No. of MA (RCTs)           13 (153)           20 (126)           17 (287)           23 (310)           NR (216)           12 (165)           12 (165)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear ink of bias withower treatment effect 0.21(-0.34 to -0 -0.29(-0.42 to -0 -0.09(-0.42 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 0.02(-0.12 to 0.1 -0.01(-0.15 to 0.1 0.02(-0.12 to 0.1 -0.17(-0.43 to 0.1 -0.17(-0.49 to 0.1
D	MA. meta-analyses; RCT, rando "Values are numbers of MA (RC Trial-level characteristi Trial-size(number of pa (large sample/small sa (large sample/small sa Baseline imbalance (nu Intention to treat analy Whether co-interventio (no/yes) Whether compliance in (yes/no) Similartiming ofoutcor (yes/no) Adequately powered/p Early stopping (no/yes (domain in Cochrane ri (low/high or unclear)	inized controlled bitk, WE, Ind inized controlled bitk, WE, Ind its stated otherwise. Statents) NU Statents NU Statents NU Statents) NU Statents NU	tudy           uesch.2010(≥100 vs <100 per arm)	No. of MA (RCTs)           13 (153)           20 (126)           7/148 (RCTs)           13 (153)           20 (126)           17 (287)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           10 (1546)           117 (287)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear mix of bias wit lower treatment effect 0.221(-0.34 to -C -0.29(-0.42 to -C -0.29(-0.42 to -C -0.09(-0.24 to 0) -0.00(-0.24 to 0) -0.00(-0.24 to 0) -0.01(-0.24 to 0) -0.01(-0.24 to 0) -0.01(-0.24 to 0) -0.05(-0.10 to 0.2 0.05(-0.10 to 0.2 0.05(-0.15 to 0.1 0.02(-0.15 to 0.1 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2) 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2) 0.05(-0.09 to 0.2) 0.05
D	MA. meta-analyses; RCT, rando <sup>™</sup> dates are numbers of MA (RC Trial-level characteristi Trial-size(number of pa (large sample/small sa Baseline imbalance (n Intention to treat analy Whether co-interventio (no/yes) Whether co-interventio (no/yes) Whether compliance is (yes/no) Adequately powered/p Early stopping (no/yes (domain in Cochrane ri (low/high or unclear) Trial registration (yes	rinized controlled bial, ME, Imited otherwise. To Juntess stated otherwise. attients) Nu mple) Bc olytes) Hi sis risis (yes/mo) Hi s acceptable? Vi Hi rise acceptable? Vi rise acc	tudy Luesch,2010(≥100 vs <100 per arm) lov/g.2018(≥128 vs <128) an Tulder,2009 empel.2012 antigi_2014(a) an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 antigi_2014 artling,2014 apageorgiou.2018	No. of MA (RCTs)           13 (153)           20 (126)           13 (153)           20 (126)           17 (287)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           13 (128)           14 (128)           15 (128)	/ unclear risk of bias Difference Trials w	0.4 0.6 n high / unclear mix of bias is high / unclear mix of bias is brever treatment effect -0.21(-0.34 to -0 -0.28(-0.42 to -0 -0.28(-0.42 to -0 -0.10(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 0.02(-0.12 to 0.1 0.02(-0.12 to 0.1 0.02(-0.12 to 0.1 0.02(-0.12 to 0.1 0.02(-0.13 to 0.1 0.017(-0.43 to 0.1 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2) 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2) 0.05(-0.09 to 0.2) 0.05(-0.00 t
)	MA. mete-analyses; RCT, rando Values are numbers of MA (RC Trial-level characteristi Trial-size(number of pa (large sample/small sa Baseline imbalance (no Intention to treat analy Whether co-interventio (nolyes) Whether co-interventio (nolyes) Whether compliance is (yes/no) Similartiming ofoutcos (yes/no) Adequately powered/p Early stopping (nolyes Other sources of blas (domain in Cochrane i (low/high or unclear) Trial registration (yes	inized confidentials, ME, Inter inized confidentials, ME, Inter tatients) Ni, mple) BC variations) Va He ins exists? Va He me assessment Va is acceptable? Va He He me assessment Va He He He He He He He He He He	tudy           uesch,2010(≥100 vs <100 per am)	-0.6           Trisies with high, show larger           13 (153)           20 (126)           13 (153)           20 (126)           17 (287)           32 (310)           NR (216)           12 (165)           1107 (1346)           17 (287)           16 (63)           17 (287)	/ unclear risk of bias Difference Trials w	0.4 0.0 In high / unclear risk of bias w lower treatment effect -0.21(-0.34 to -0 -0.29(-0.42 to -0 -0.09(-0.24 to 0.0 -0.07(-0.28 to 0.1 -0.07(-0.28 to 1.0 -0.07(-0.28 to 1.0 -0.07(-0.28 to 1.0 -0.07(-0.28 to 1.0 -0.07(-0.28 to 1.0 -0.05(-0.10 to 0.2 0.09(-0.05 to 0.2 0.09(-0.15 to 0.2 0.09(-0.15 to 0.1 0.02(-0.15 to 0.1 0.02(-0.15 to 0.1 0.17(-0.43 to 0.1 -0.17(-0.43 to 0.1 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2 -0.36(-0.06 to -0.0 0.02(-0.13 to 0.1) -0.02(-0.13 to 0.1)
b	MA. meta-analyses; RCT, rando <sup>™</sup> dates are numbers of MA (RC Trial-level characteristi Trial-size(number of pa (large sample/small sa Baseline imbalance (n Intention to treat analy Whether co-interventio (no/yes) Whether co-interventio (no/yes) Whether compliance is (yes/no) Adequately powered/p Early stopping (no/yes (domain in Cochrane ri (low/high or unclear) Trial registration (yes	rized controlled visit, ME, Inne rize doubled visit, ME, Inne statients) NI mple) B visit (ves/no) Vi rise acceptable? Vi rise acceptable? Vi rine s acceptable? Vi Hi reme assessment Vi rine s acceptable? Tr Hi rine s acceptable? Tr Hi rine (Tr) Hi rine (Tr) Hi Hi rine (Tr) Hi rine (Tr) Hi rine (Tr) Hi	tudy Luesch,2010(≥100 vs <100 per arm) lov/g.2018(≥128 vs <128) an Tulder,2009 empel.2012 antigi_2014(a) an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 empel.2012 an Tulder,2009 antigi_2014 artling,2014 apageorgiou.2018	No. of MA (RCTs)           13 (153)           20 (126)           13 (153)           20 (126)           17 (287)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           13 (128)           14 (128)           15 (128)	Indear risk of bias     Difference     The w     is c	0.4 0.6 m high / unclear insk of blas in loge / unclear insk of blas is tower treatment effect -0.21(-0.34 to -( -0.28(-0.42 to -( -0.28(-0.42 to -( -0.06(-0.24 to 0) -0.07(-0.28 to 0) -0.07(-0.28 to 0) -0.07(-0.28 to 0) -0.07(-0.28 to 0) -0.07(-0.28 to 0) -0.07(-0.24 to 0) 0.05(-0.10 to 0.2 0.05(-0.15 to 0.2 -0.01(-0.15 to 0.2 -0.05(-0.15 to 0.2) -0.05(-0.15 to 0.2 -0.05(-0.15 to 0.2) -0.05(-0.15 to 0.2) -0.05(-0
b	MA. mete-analyses; RCT, rando <sup>™</sup> dutes are numbers of MA (RC Trial-level characteristi Trial-size(number of pa (large sample/small sa Baseline imbalance (no Intention to treat analy Whether co-interventio (nolyes) Whether co-interventio (nolyes) Whether compliance is (yes/no) Similartiming ofoutcol (yes/no) Adequately powered/p Early stopping (nolyes) Other sources of bias (domain in Cochrane i (low/high or unclear) Trial registration (yes Industry funding (noly Mutticenter/single-cer Individual RCT/cluster	inized controlled bial, ME, Infe inized controlled bial, ME, Infe tatients) Nu mple) BC 0/yes) H4 H4 me assessment V2 s acceptable? V2 H4 H4 me assessment V2 isk of bias) H4 isk of bias) H4 RCT Le	Ludy           uesch.2010(≥100 vs <100 per arm)	No. of MA (RCTs)           13 (153)           20 (126)           13 (153)           20 (126)           12 (165)           17 (287)           23 (163)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           NR (216)           12 (165)           107 (1346)           117 (287)           16 (83)           17 (287)           26 (292)	Indear risk of bias     Difference     The w     is c	0.4 0.6 n high / unclear mix of bias is high / unclear mix of bias is brever treatment effect -0.21(-0.34 to -0 -0.28(-0.42 to -0 -0.28(-0.42 to -0 -0.10(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.00(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 -0.01(-0.24 to 0.0 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 0.05(-0.15 to 0.2 0.02(-0.12 to 0.1 0.02(-0.12 to 0.1 0.02(-0.12 to 0.1 0.02(-0.12 to 0.1 0.02(-0.13 to 0.1 0.017(-0.43 to 0.1 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2) 0.05(-0.09 to 0.2 0.05(-0.09 to 0.2) 0.05(-0.09 to 0.2) 0.05(-0.00 t

	Trial-level characteris	tics Subgroup (	(type of outcome)	No. of MA	(RCTs)*		Ratio of effect size (95%CI)
		Objective o					
		Wood, 2008 Savovic,2012		62 (484) 32 (268)			0.91(0.80 to 1.03) 0.98(0.88 to 1.10)
		Savovic,2012	(objective outcomes other than mortality)	45 (372)		-	0.97(0.85 to 1.10)
		Chaimani,20 Dechartres,2		NR (123) 55 (NR)			1.05(0.56 to 1.75) 0.86(0.78 to 0.95)
		Page,2016(m	ortality)	3 ME studie		- <b>-</b>	1.02(0.91 to 1.13)
		Page,2016(o Savovic,2018	bjective outcomes other than mortality) 3(mortality)	3 ME studie 35 (358)		•	1.03(0.74 to 1.43) 0.84(0.71 to 1.01)
	Allocation concealment		(objective outcomes other than mortality)	49 (524) 8 (57)	-	<u> </u>	0.96(0.86 to 1.07) 1.62(0.69 to 3.77)
		Subjective Wood, 2008	outcome	40 (320)	-+	_	0.69(0.59 to 0.82)
		Savovic,2012 Dechartres,2	2(subjective or mixed outcomes)	69 (652) 69 (NR)		÷.	0.85(0.75 to 0.95) 0.88(0.80 to 0.97)
		Page,2016	014	4 ME studie			0.80(0.71 to 0.90)
		Savovic,2018 Haring,2020(	3 patient-reported)	104 (1239) 6 (54)			0.91(0.83 to 0.99) 0.75(0.52 to 1.08)
		Double blin Objective					
		Savovic,201	2(mortality)	25 (245) 28 (282)			0.92(0.80 to 1.04) 0.93(0.74 to 1.18)
		Dechartres,2	2(objective outcomes other than mortality) 2014	26 (202) 25 (NR)	-	-	0.79(0.67 to 0.93)
	Page,2016 Haring,2020			2 ME studie 10 (68)	26 (NR)		1.04(0.86 to 1.27) - 0.97(0.50 to 1.87)
		Subjective		51 (530)	_		0.78(0.65 to 0.92)
		Dechartres,2	2(subjective or mixed outcomes) 2014	51 (NR)	_	- 	0.83(0.68 to 0.99)
		Haring,2020	(patient-reported)	6 (54)			
			outcome assessor				
	Blinding	Objective of Haring,2020	outcome	5 (36)			0.55(0.20 to 1.54)
		Subjective					0.96(0.54 to 1.73)
			(patient-reported)	5 (49)			0.96(0.54 to 1.73)
		Objective	patients, health professionals and outo outcome				1.01(0.92 to 1.10)
		Wood,2008 Savovic,201	8(mortality)	44 (437) 31 (327) 22 (234)	-	•	0.83(0.72 to 0.97)
			B(objective outcomes other than mortality)	32 (334)			0.94(0.81 to 1.10)
		Subjective Wood,2008 Savovic,201		32 (309) 81 (1017)	_	- -	0.75(0.61 to 0.82) 0.83(0.73 to 0.93)
					0 0.5 Trials with blob / unclear risk of blas	1 1.5 Ratio Trials with high / unc	2
	MA, meta-analyses; RCT, ran "Values are numbers of MA(R	domized controlled trial; Cl CTs) unless stated otherw	I, confidence interval; ME, meta-epidemiological; NR vise.	, not reported	show larger treatment effect	show lower treat	ment effect
b	Trial	-level characteristics	Subgroup (type of outcome)	No. of MA (RCTs)*			Difference of effect size (95%CI)
			Objective outcome				
			Hartling,2014	11 (178)			0.25(-0.06 to 0.56)
			Armijo-Olivo,2015	NR			0.09(-0.31 to 0.49)
			Armijo–Olivo,2015 Saltaji,2018(a)			+	
	Allo	cation concealment	Saltaji,2018(a)	NR			0.09(-0.31 to 0.49)
	Allo	cation concealment		NR			0.09(-0.31 to 0.49)
	Allor	cation concealment	Saltaji,2018(a) Subjective outcome Hartling,2014 Armijo~Olivo,2015	NR NR 6 (109) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33)
	Allo	cation concealment	Saltaji,2018(a) Subjective outcome Hartling,2014	NR NR 6 (109)	 		0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06)
	Allo	cation concealment	Saltaji,2018(a) Subjective outcome Harting,2014 Armijo-Olivo,2015 Saltaji,2018(a) Double blinding	NR NR 6 (109) NR	 		0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.03) -0.15(-0.29 to -0.01)
	Allo	cation concealment	Saltaji,2018(a) Subjective outcome Harting,2014 Armijo-Olivo,2015 Saltaji,2018(a) Double bilinding Objective outcome	NR NR 6 (109) NR NR	 		0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) 
	Allor	cation concealment	Saltaji,2018(a) Subjective outcome Harting,2014 Armijo-Olivo,2015 Saltaji,2018(a) Double blinding	NR NR 6 (109) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01)
	Alloo	cation concealment	Saltaji,2018(a) Subjective outcome Harting,2014 Armije-Olivo,2015 Saltaji,2018(a) Double bilinding Objective outcome Harting,2014	NR NR NR NR 11 (178)			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.05 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.05 to 0.24) -0.42(-1.03 to 0.19)
	Alfor	cation concealment	Saltaji.2018(a) Subjective outcome Harting.2014 Armija-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014	NR NR 6 (109) NR NR 11 (178) NR ← 6(109)	  		0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.05(-0.29 to -0.01) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06)
	Ailo:	cation concealment	Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome	NR NR NR NR 11 (178) NR ←			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.06 to 0.24) -0.42(-1.03 to 0.19)
	Ailor 	cation concealment	Saltaji,2018(a) Subjective outcome Harting,2014 Armije-Oivo,2015 Sattaji,2018(a) Objective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Sattaji,2018(b) Bilinding of patients	NR NR 6 (109) NR NR 11 (178) NR ← 6(109)			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.05(-0.29 to -0.01) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06)
	Alloc	cation concealment	Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome	NR NR 6 (109) NR 11 (178) NR 6(109) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.42(-1.03 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07)
	Alfor	ation concealment	Saltaji.2018(a) Subjective outcome Hartling.2014 Armije-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Hartling.2014 Saltaji.2018(b) Subjective outcome Hartling.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016	NR NR 6 (109) NR NR 11 (178) NR 6(109) NR 1 ME studies (NR)			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.05 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06)
	Alfor	cation concealment	Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome	NR NR 6 (109) NR 11 (178) NR 6(109) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.05 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18)
	Alfor	cation concealment	Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017	NR NR 6 (109) NR NR 6 (109) NR 6 (109) NR 1 ME studies (NR) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.05(-0.29 to -0.01) -0.42(-1.03 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26)
	Alloc	cation concealment	Sattaji,2018(a) Subjective outcome Harting,2014 Armije-Olivo,2015 Sattaji,2018(a) Objective outcome Harting,2014 Sattaji,2018(b) Subjective outcome Harting,2014 Sattaji,2018(b) Bilinding of patients Objective outcome Page,2016 Subjective outcome Page,2016	NR NR 6 (109) NR NR 11 (178) NR 6(109) NR 1 ME studies (NR) NR NR 2 ME studies (NR)			0.094-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.05 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.05 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.21 to 0.07) -0.02(-0.21 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017	NR NR 6 (109) NR NR 6 (109) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.15(-0.29 to -0.01) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.04) -0.07(-0.21 to 0.07) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32)
	Allor		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2016(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b)	NR NR 6 (109) NR NR 11 (178) NR 6(109) NR 1 ME studies (NR) NR NR 2 ME studies (NR)			0.094-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.39 to 0.06) 0.12(-0.05 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.05 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.21 to 0.07) -0.02(-0.21 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Blinding of outcome assessors	NR NR 6 (109) NR NR 6 (109) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.15(-0.29 to -0.01) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.04) -0.07(-0.21 to 0.07) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32)
	_		Sattaji.2018(a) Subjective outcome Harting.2014 Armije-Olivo,2015 Sattaji.2018(a) Objective outcome Harting.2014 Sattaji.2018(b) Subjective outcome Harting.2014 Sattaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Sattaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Sattaji.2018(b) Blinding of outcome Page.2016 Armijo-Olivo.2017 Sattaji.2018(b) Blinding of outcome Blinding of outcome assessors Objective outcome	NR NR NR NR 11 (178) NR 6(109) NR 1 ME studies (NR) NR NR 2 ME studies (NR) NR NR NR NR			0.094-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.122-0.09 to 0.33) -0.15(-0.29 to -0.01) 0.10(-0.05 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.122-0.08 to 0.32) -0.11(-0.23 to 0.01)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Blinding of outcome assessors	NR NR 6 (109) NR NR 6 (109) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.15(-0.29 to -0.01) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.04) -0.07(-0.21 to 0.07) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Double blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Blinding of outcome assessors Objective outcome Harting.2014	NR 6 (109) NR NR 11 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 11 (178)			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.24 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.15(-0.29 to -0.01) -0.42(-1.03 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) -0.08(-0.10 to 0.25)
	_		Sattaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Sattaji.2018(a) Duble bilnding Objective outcome Harting.2014 Sattaji.2018(b) Subjective outcome Harting.2014 Sattaji.2018(b) Bilnding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Sattaji.2018(b) Subjective outcome Harting.2016 Bilnding of outcome assessors Objective outcome Harting.2014 Sattaji.2018(b) Subjective outcome Harting.2014 Sattaji.2018(b) Subjective outcome Harting.2014 Sattaji.2018(b) Subjective outcome Harting.2014 Sattaji.2018(b) Subjective outcome Harting.2014 Sattaji.2018(b)	NR NR 6 (109) NR NR 11 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 2 ME studies (NR) NR 11 (178) NR 6 (109) 11 (178) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.05(-0.29 to -0.01) -0.06(-0.17 to 0.04) -0.07(-0.21 to 0.07) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) -0.08(-0.10 to 0.25) 0.08(-0.10 to 0.25) 0.09(-0.25 to 0.43)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armije-Olivo,2015 Saltaji.2018(a) Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Bilinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Bilinding of outcome assessors Objective outcome Harting.2014 Saltaji.2018(b) Bilinding of outcome assessors Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b)	NR NR 6 (109) NR NR 11 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 1 ME studies (NR) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.16(-0.39 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.06(-0.17 to 0.04) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.16) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) 0.08(-0.10 to 0.25) 0.09(-0.25 to 0.43)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Duble blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Blinding of outcome Saltaji.2018(b) Blinding of outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of outcome Harting.2014 Saltaji.2018(b) Blinding of outcome Blinding of outcome Harting.2014 Saltaji.2018(b) Blinding of outcome Blinding.2014 Saltaji.2018(b) Blinding.2014 Saltaji.2018(b) Blinding of patients and assessors	NR NR 6 (109) NR NR 11 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 2 ME studies (NR) NR 11 (178) NR 6 (109) 11 (178) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.05(-0.29 to -0.01) -0.06(-0.17 to 0.04) -0.07(-0.21 to 0.07) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) -0.08(-0.10 to 0.25) 0.08(-0.10 to 0.25) 0.09(-0.25 to 0.43)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armije-Olivo,2015 Saltaji.2018(a) Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Bilinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Bilinding of outcome assessors Objective outcome Harting.2014 Saltaji.2018(b) Bilinding of outcome assessors Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b)	NR NR 6 (109) NR NR 11 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 2 ME studies (NR) NR 11 (178) NR 6 (109) 11 (178) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.05(-0.29 to -0.01) -0.06(-0.17 to 0.04) -0.07(-0.21 to 0.07) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) -0.08(-0.10 to 0.25) 0.08(-0.10 to 0.25) 0.09(-0.25 to 0.43)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armijo-Olivo.2015 Saltaji.2018(a) Doble blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Subjective outcome Page.2016 Armijo-Olivo.2017 Saltaji.2018(b) Blinding of outcome assessors Objective outcome Harting.2014 Saltaji.2018(b) Blinding of outcome assessors Objective outcome Harting.2014 Saltaji.2018(b) Blinding of patients and assessors Objective outcome Harting.2014	NR NR 11 (178) NR 6(109) NR 6(109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 11 (178) NR 11 (178) NR 6 (109) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.06(-0.17 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 1.06) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) 0.08(-0.10 to 0.25) 0.09(-0.25 to 0.43) 0.07(-0.18 to 0.05) -0.08(-0.21 to 0.05)
	_		Saltaji,2018(a) Subjective outcome Harting,2014 Armije-Olivo,2015 Saltaji,2018(a) Objective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Bilnding of patients Objective outcome Page,2016 Armijo-Olivo,2017 Saltaji,2018(b) Subjective outcome Page,2016 Armijo-Olivo,2017 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Bilnding of outcome assessors Objective outcome Harting,2014 Saltaji,2018(b) Bilnding of outcome assessors Objective outcome Harting,2014 Saltaji,2018(b) Bilnding of patients and assessors Objective outcome	NR NR 11 (178) NR 6(109) NR 6(109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 11 (178) NR 11 (178) NR 6 (109) NR			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.06(-0.17 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 1.06) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) 0.08(-0.10 to 0.25) 0.09(-0.25 to 0.43) 0.07(-0.18 to 0.05) -0.08(-0.21 to 0.05)
	_		Saltaji.2018(a) Subjective outcome Harting.2014 Armije-Olivo.2015 Saltaji.2018(a) Ouble blinding Objective outcome Harting.2014 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients Objective outcome Page.2016 Armije-Olivo.2017 Saltaji.2018(b) Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of outcome sessors Objective outcome Harting.2014 Saltaji.2018(b) Blinding of patients and sessors Objective outcome Harting.2014 Saltaji.2018(b) Blinding of patients and sessors Objective outcome Harting.2014 Saltaji.2018(b) Blinding of patients and sessors Objective outcome Subjective outcome Harting.2014 Saltaji.2018(b) Blinding of patients and sessors Objective outcome Saltaji.2018(b)	NR 6 (109) NR NR 11 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 2 ME studies (NR) NR 11 (178) NR 6 (109) NR 11 (178) NR 6 (109) NR 11 (178) 12 (109) NR 13 (109) 14 (109) 15 (109) 16 (109) 17 (109) 17 (109) 18 (109) 1			0.08(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.18(-0.24 to 0.06) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.02(-0.29 to -0.01) -0.02(-0.29 to -0.01) -0.02(-0.21 to 0.07) -0.02(-0.21 to 0.07) -0.02(-0.21 to 0.07) -0.02(-0.21 to 0.05) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) -0.09(-0.25 to 0.43) 0.09(-0.25 to 0.43) 0.07(-0.18 to 0.05) -0.08(-0.21 to 0.05) -0.08(-0.21 to 0.05) -0.07(-3.86 to 2.32) -0.19(-0.32 to -0.06)
	Bilin	ding	Saltaji,2018(a) Subjective outcome Harting,2014 Armije-Olivo,2015 Saltaji,2018(a) Objective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Bilinding of patients Objective outcome Page,2016 Armijo-Olivo,2017 Saltaji,2018(b) Subjective outcome Page,2016 Armijo-Olivo,2017 Saltaji,2018(b) Bilinding of outcome assessors Objective outcome Harting,2014 Saltaji,2018(b) Bilinding of outcome assessors Objective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Bilinding of outcome assessors Objective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Harting,2014 Saltaji,2018(b) Subjective outcome Saltaji,2018(b)	NR NR 6 (109) NR NR 111 (178) NR 6 (109) NR 1 ME studies (NR) NR 2 ME studies (NR) NR 2 ME studies (NR) NR 111 (178) NR 111 (178) NR			0.09(-0.31 to 0.49) -0.14(-0.44 to 0.16) -0.14(-0.44 to 0.16) 0.12(-0.09 to 0.33) -0.15(-0.29 to -0.01) -0.15(-0.29 to -0.01) -0.42(-1.03 to 0.24) -0.42(-1.03 to 0.24) -0.42(-1.03 to 0.19) -0.06(-0.17 to 0.06) -0.07(-0.21 to 0.07) -0.02(-0.22 to 0.18) 0.10(-0.40 to 0.59) -0.30(-0.87 to 0.26) -0.37(-0.77 to 0.04) 0.12(-0.08 to 0.32) -0.11(-0.23 to 0.01) -0.09(-0.25 to 0.43) 0.09(-0.25 to 0.43) 0.07(-0.18 to 0.05) -0.08(-0.11 to 0.25) 0.09(-0.25 to 0.43) 0.07(-0.18 to 0.05) -0.08(-0.21 to 0.05) -0.08(-0.21 to 0.05) -0.09(-0.23 to -0.06)

were only seen in trials with pharmacological intervention, using inactive control, focusing on complementary medicine and included in non-Cochrane review other than trials with non-pharmacological intervention, using active control, focusing on non-complementary medicine and included in Cochrane review (Additional file 11: Appendix 11-B-2, Appendix 11-B-3, Additional file 12: Appendix 12-B-1). For continuous outcomes, larger treatment effect estimates for trials with high or unclear risk of bias on blinding of participants were only demonstrated in non-pharmacological intervention trials (Additional file 11: Appendix 11-C-2), while the associations between treatment effect estimates and risk of bias for both blinding of participants and allocation concealment were only seen in complementary medicine trials (Additional file 11: Appendix 11-C-4). It is worth noted that larger treatment effect estimates in first trial as compared with subsequent trial were consistently observed regardless of the sample size (< 300 and > 300), risk of bias (low, unclear and high) or effect size ( $\leq 0.5$  SMDs and > 0.5SMDs) of the first trial for continuous outcomes (Additional file 12: Appendix 12-C-1). Such consistency has not been explored for binary outcomes. Details on subgroup analyses for both binary and continuous outcomes were displayed in Fig. 4, Additional file 11: Appendix 11 and Additional file 12: Appendix 12.

#### Discussion

This systematic review identified 80 ME studies on intervention field, with almost one-third uncovered by the previous systematic reviews [15, 16]. The included ME studies covered various medical areas and interventions. An abundant of trial-level characteristics have been evaluated, varied from risk of bias domains (e.g., blinding) to language (English and non-English), and age of participants (e.g., children and adult), with allocation concealment, sequence generation and blinding being most commonly evaluated. On average, consistently significant associations with larger treatment effect estimates were observed in trials with high or unclear (versus low) risk of bias on sequence generation, allocation concealment, double blinding and smaller sample size. For allocation concealment and double blinding, the significant associations were more frequently observed in subjective outcomes. The impacts of missing outcome data and intention-to-treat included in the Cochrane RoB2 tool were uncertain. Furthermore, some characteristics in the Cochrane RoB2 tool have not been covered by the included ME studies yet, including using a validated method for outcome measures and selection of the reported results from multiple outcome measures or multiple analysis based on results (e.g., significance of the results).

Besides larger number and more updated ME studies were included when compared to the previous systematic reviews [15, 16], we identified some interesting findings in the subgroup analyses: i) High or unclear risk of bias on blinding of outcome assessors were significantly associated with larger treatment effect estimates in trials using single observer for non-blinded assessment for both binary and continuous outcomes. This finding indicates that when blinding of outcome assessor is not possible, reaching consensus by multiple assessors might be an alternative strategy to reduce potential detection bias; ii) larger treatment effect estimates for trials published in non-English (binary outcome), trials with high or unclear risk of bias on blinding of participants (continuous outcome) and allocation concealment (continuous outcome) were only seen in trials focusing on complementary medicine. A tentative explanation for the differences between these subgroups is that trials on complementary medicine had a higher probability of suffering from methodological flaws [31]; iii) larger treatment effect estimates in first trial as compared with subsequent trial were consistently observed, regardless of the trial size, risk of bias or effect size of the first trial for continuous outcomes, indicating the robustness of the association. However, such explorations are missing in binary outcomes, although inconsistencies were observed between the two available ME studies [29, 30]. That invites future ME studies to address.

Several reporting and methodological flaws among the sampled ME studies are worth to be noted. Over onefifth ME studies missed reporting some key information such as funding sources, criteria used for selecting one meta-analysis within each systematic review and management of overlapping meta-analyses. Future ME studies are suggested to follow the corresponding reporting guideline [32] to improve their reporting and transparency. Commonly methodological flaws waiting for future ME studies to overcome included assessing the methodological quality of included studies, publishing a protocol, and providing a list of excluded studies with reasons. Furthermore, before the availability of a guideline for conducting ME studies, future ME studies could at least refer to existing publications regarding the statistical methods [33–35] and sample size [36] of a ME study.

Several additional key points regarding the conducting of ME studies worth discussed as well. Some preliminary steps are needed to reduce potential bias [37, 38] before combing differences in treatment effect estimates across meta-analyses or trials in a ME study. First, with regards to management of overlapping, using a study more than one time in the same quantitative analysis may overstate its sample size and number of events. Although it may produce greater precision and better robustness of the conclusions, the conclusion would be wrong [39]. However, almost half of the ME studies did not report whether overlapping meta-analyses were managed, which calls attentions from the future ME studies. Second, ensure the results from different meta-analyses have the same sense of interpretation [15] by checking experimental and control arm in each trial when two active interventions are compared [38], and reclassifying outcomes (e.g., survival re-coded as mortality) if needed [15]. However, only half of the ME studies reported information on whether experimental and control arm had been checked.

While using data from meta-analyses to assess the difference in treatment effect estimates, the results might be distorted by the presence of within- and between-metaanalysis heterogeneity if the clustering of trials within meta-analysis is not accounted for [40]. That was observed in more than 10% related ME studies. Being observational studies in nature, ME studies are generally at risk of confounding [38]. Despite repeated emphases [16, 33, 41], ME studies that completely controlled confounders are rare [42]. About four-fifth of the included ME studies adjusted meta-confounders, which have been improved compared to the previous systematic reviews [15, 16]. However, 59% adjusted confounders solely based on subgroup analysis, with very limited number of confounders being controlled at one time, indicating incomplete control of confounding. Alternatively, multiple variable analysis could be a better choice. Meanwhile, the selection of potential confounders is challenging, besides empirical evidence and theoretical consideration, the directed acyclic graph (DAG) approach proposed by Herbert [37] is recommended. Additionally, ME studies based on collection of trials could also reduce confounding through comparison within the same trial (e.g., compare blinding with non-blinding assessment) [15].

Further issues regarding confounding are that the association between blinding and treatment effect estimates were more consistent when more than one party (participants and assessors with/without personnel) was considered simultaneously as double blinding for both binary and continuous outcomes. During trial reporting, the CONSORT statement [43] encourages trial author to clearly state who is blinded rather than ambiguously state double blinding. However, in ME studies, blinding of different parties was generally correlated with each other (e.g., blinding of participants and blinding of personnel), accordingly, analyzing these parties separately without controlling the remaining ones might introduce confounding bias. Therefore, combining the three key parties (participants, personnel and outcome assessors) as one group might be an optimal choice for reducing confounding bias in ME studies. Similar consideration is needed for allocation concealment. We agree with Moustgaard et. al [1] that theoretically, the association between allocation concealment and treatment effect estimates should not depend on type of outcome (subjective or objective), which disagreed with available ME studies [16]. In theory, the confounding of blinding could be a major concern under such scenario. It is difficult to implement blinding especially blinding of participants and personnel when allocation sequence is unconcealed. Careful considerations of other confounders as well as the relationship among different trial characteristics are needed for future ME studies.

As agreeing with the previous systematic reviews [15, 16], this review also found that significant associations between trial-level characteristics and treatment effect estimates were much frequently seen in binary outcomes than that of continuous outcomes, including subgroup analyses. Larger sample of meta-analyses with more homogeneous data on binary outcomes [44] might contribute to the differences [15]. Although it have been raised by the previous systematic review [15], more attentions are still needed on continuous outcome for the future ME studies as results based on binary outcome may not be directly generalized to continuous outcome.

#### Strengths and limitations

This systematic review has several strengths. First, no limit on medical areas and type of interventions ensured the generalizability of our results. Second, methodological quality of included ME studies has been assessed to inform where improvements are needed in the future. Third, comprehensive information related to subgroup analyses was extracted, and interesting subgroups like bias introduced by lack of blinding of outcome assessors might be removed by adopting multiple observer consensus [2] have been identified.

Some apparent limitations are worth noted in our study. First, some ME studies sometimes use "methodo-logical study" or "research on research" to describe [45]. However, we directly adopted the literature search strategies from the previously published systematic review [15] to identify eligible ME studies. That did not include the aforementioned search terms, which probably led to missing some potentially eligible studies.

Second, there was no specific tool for assessing the methodological quality of ME studies. Therefore, we used a self-developed criterion through discussing within group members, without consulting external specialists.

Third, we extracted the results of unadjusted analysis for each ME study as nearly three-fifth ME studies adjusted confounders using subgroup analysis rather than multiple variables analysis (32/54, 59%) or did not report adjusted results (13/22, 59%). Fourth, we did not combine the results quantitatively either for the main analyses or subgroup analyses due to the potential overlapping of meta-analyses and trials. Although we presented the results by considering both the statistically significant differences and the direction of treatment effect estimates to reduce the impact of solely based on vote counting. Without quantitative combination, the potential influence of Simpson's paradox might not be completely removed. Furthermore, while conducting an ME study, duplications should be considered and removed [39]. However, among the 63 included ME studies based on collection of meta-analyses, only 35 (56%) managed the overlaps of RCTs. That calls for future ME studies to pay attention to the duplicated RCTs, especially when quantitative synthesis is conducted.

Fifth, only ME studies on intervention field were considered. Results from this review may not be generalized to other fields of ME studies, such as diagnosis accuracy [46–48], prognostic study [49, 50], and prediction models [51].

Sixth, related information of methodology and reporting was extracted based on publications, which may introduce bias if authors did not conduct as reported or did not report related information.

#### Implications

Identifying trial-level characteristics that impact the treatment effect estimates is critical for both trial design and critical appraisal in the era of evidence-based medicine. In this updated systematic review, we collected additional empirical evidence about the associations between trial-level characteristics and treatment effect estimates. Authors of RCTs are suggested to account for trial characteristic that are significantly associated with treatment effect estimates, like sequence generation, allocation concealment, blinding and sample size when designing and conducting RCTs. When it is difficult to blind outcome assessors, a multiple assessors consensus strategy could be an alternative approach to reduce detection bias. When assessing the impact of blinding on treatment effect estimates in ME studies, combing the three key parties (participants, personnel and outcome assessors) of blinding as one group might reduce potential confounding.

#### Conclusions

We found consistently significant associations between treatment effect estimates and sequence generation, allocation concealment, double blinding and sample size. The associations between treatment effect estimates and allocation concealment and double blinding were more consistent in trials using subjective outcomes. More ME studies are needed to assess the impact of trial characteristics in the Cochrane RoB2 tool without sufficient empirical evidence supported currently, including missing outcome data, intentionto-treat, methods used for outcome measures and selection of the reported results from multiple outcome measures or multiple analysis based on results (e.g., significance of the results). Furthermore, the methodological and reporting quality of included ME studies are dissatisfactory. Future researchers are recommended to reporting ME studies following the corresponding guideline [32]. Specific guidelines for conducting ME studies and assessing the methodological quality of ME studies are needed as well.

#### Abbreviations

ME: Meta-epidemiological; RoB2: Cochrane risk-of-bias 2; RCT: Randomized controlled trial; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; ICD-11: International Classification of Diseases 11th version; ROR: Ratio of odds ratio; AMSTAR 2: A MeaSurement Tool to Assess systematic Reviews-2; CI: Confidence interval; SMD: Standardized mean difference; DAG: Directed acyclic graph.

#### Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12874-022-01650-5.

Additional file 1: Appendix 1. Search strategy.

Additional file 2: Appendix 2. Bibliographical characteristics.

Additional file 3: Appendix 3. Methodological quality of meta-epidemiological (ME) studies.

Additional file 4: Appendix 4. List of included 80 meta-epidemiological studies.

Additional file 5: Appendix 5. List of excluded meta-epidemiological (ME) studies based on full text with reasons.

Additional file 6: Appendix 6. Number of meta-epidemiological studies on trial-level characteristics related to treatment effect estimates published by year.

Additional file 7: Appendix 7. Main characteristics of 80 meta-epidemiological (ME) studies.

Additional file 8: Appendix 8. Trial-level characteristics evaluated in 80 meta-epidemiological (ME) studies by chroNological order.

Additional file 9: Appendix 9. Details on the subgroup analyses in 48 meta-epidemiological (ME) studies.

Additional file 10: Appendix 10. Associations between treatment effect estimates and other trial-level characteristics for binary outcome.

Additional file 11: Appendix 11. Associations between treatment effect estimates and trial-level characteristics according to different subgroup analyses.

Additional file 12: Appendix 12. Results of additional subgroup analyses.

#### Acknowledgements

None.

#### Authors' contributions

IW conceived and designed the research questions. HW conducted the literature search. HW and JL performed the literature selection. HW, JL, WJ, YY, LQ and YC extracted data. HW, JL and YL conducted the critical appraisal. HW and JL analyzed data. IW, HW and JL interpreted the results. HW and JL wrote the manuscript under the supervision of IW, VC and WT. All authors had full access to all the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. IW is the guarantor. The authors read and approved the final manuscript.

#### Funding

This research was supported by the National Natural Science Foundation of China (81973709), Hunan Nature Science Foundation (2019JJ40348) and the High-level Talents Introduction Plan from Central South University (502045003),

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

#### Declarations

#### Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

#### **Consent for publication**

For this type of study, formal consent is not required.

#### **Competing interests**

None.

#### Author details

<sup>1</sup>5/F, Xiangya School of Public Health, No. 238, Shang-ma-yuan-ling Alley, Kaifu district, Changsha, China. <sup>2</sup>Alice Lee Centre for Nursing Studies, National University of Singapore, Singapore, <sup>3</sup>Hunan Provincial Key Laboratory of Clinical Epidemiology, Changsha, Hunan, China. <sup>4</sup>Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. <sup>5</sup>School of Chinese Medicine, The Chinese University of Hong Kong, China.

#### Received: 11 January 2022 Accepted: 26 May 2022 Published online: 15 June 2022

#### References

- Moustgaard H, Clayton GL, Jones HE, Boutron I, Jørgensen L, Laursen DRT, Olsen MF, Paludan-Müller A, Ravaud P, Savović J, et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ (Clinical research ed). 2020;368:16802.
- Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and nonblinded outcome assessors. BMJ (Clinical research ed). 2012;344:e1119.
- Dechartres A, Ravaud P, Atal I, Riveros C, Boutron I: Association between trial registration and treatment effect estimates: a meta-epidemiological study. BMC Med. 2016;14(1):1–9.
- Papageorgiou SN, Antonoglou GN, Tsiranidou E, Jepsen S, Jäger A. Bias and small-study effects influence treatment effect estimates: a meta-epidemiological study in oral medicine. J Clin Epidemiol. 2014;67(9):984–92.
- Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med. 2011;155(1):39–51.
- Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical research ed). 2008;336(7644):601–5.
- Herbison P, Hay-Smith J, Gillespie WJ. Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study. J Clin Epidemiol. 2011;64(10):1070–5.
- Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in metaanalyses. JAMA. 2014;312(6):623–30.

- Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982–9.
- Chaimani A, Vasiliadis HS, Pandis N, Schmid CH, Welton NJ, Salanti G. Effects of study precision and risk of bias in networks of interventions: a network meta-epidemiological study. Int J Epidemiol. 2013;42(4):1120–31.
- Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ (Clinical research ed). 2013;346:f2304.
- 12. Unverzagt S, Prondzinsky R, Peinemann F. Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review. J Clin Epidemiol. 2013;66(11):1271–80.
- 13. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [www.training.cochrane.org/handbook]
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2019;366:14898.
- Dechartres A, Trinquart L, Faber T, Ravaud P. Empirical evaluation of which trial characteristics are associated with treatment effect estimates. J Clin Epidemiol. 2016;77:24–37.
- Page MJ, Higgins JPT, Clayton G, Sterne JAC, Hróbjartsson A, Savović J: Empirical evidence of study design biases in randomized trials: Systematic review of meta-epidemiological studies. PLoS ONE. 2016;11(7):e0159267.
- Khan KS, Daya S, Collins JA, Walter SD. Empirical evidence of bias in infertility research: overestimation of treatment effect in crossover trials using pregnancy as the outcome measure. Fertil Steril. 1996;65(5):939–45.
- Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, Als-Nielsen B, Balk E, Gluud C, Gluud L, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess (Winchester, England). 2012;16(35):1–82.
- Dechartres A, Atal I, Riveros C, Meerpohl J, Philippe R. Association between publication characteristics and treatment effect estimates a meta-epidemiologic study. Ann Intern Med. 2018;169(6):385–93.
- Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from metaanalyses of randomized trials. Int J Epidemiol. 2007;36(4):847–57.
- Haring R, Ghannad M, Bertizzolo L, Page MJ. No evidence found for an association between trial characteristics and treatment effects in randomized trials of testosterone therapy in men: a meta-epidemiological study. J Clin Epidemiol. 2020;122:12–9.
- 22 Berthelsen DB, Ginnerup-Nielsen E, Juhl C, Lund H, Henriksen M, Hróbjartsson A, Nielsen SM, Voshaar M, Christensen R. Controversy and debate on meta-epidemiology. Paper 1: Treatment effect sizes vary in randomized trials depending on the type of outcome measure. J Clin Epidemiol. 2020;123:27–38.
- Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n160.
- Herbison P, Hay-Smith J, Gillespie WJ. Adjustment of meta-analyses on the basis of quality scores should be abandoned. J Clin Epidemiol. 2006;59(12):1249–56.
- Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, Au Peh C, Szpirt W, Ito-Hara T, Jayne DRW. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ (Clinical research ed). 2022;376: e064604.
- Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, Lay-Flurrie S, Koshiaris C, McManus RJ, Hobbs FDR, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ (Clinical research ed). 2021;374: n1537.
- Delgado-Rodriguez M, Ruiz-Canela M, De Irala-Estevez J, Llorca J, Martinez-Gonzalez A. Participation of epidemiologists and/or biostatisticians and methodological quality of published controlled clinical trials. J Epidemiol Community Health. 2001;55(8):569–72.
- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, et al. AMSTAR 2: a critical appraisal tool for

systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical research ed). 2017;358: j4008.

- Alahdab F, Farah W, Almasri J, Barrionuevo P, Zaiem F, Benkhadra R, Asi N, Alsawas M, Pang Y, Ahmed AT, et al. Treatment effect in earlier trials of patients with chronic medical conditions: a meta-epidemiologic study. Mayo Clin Proc. 2018;93(3):278–83.
- Gartlehner G, Dobrescu A, Evans TS, Thaler K, Nussbaumer B, Sommer I, Lohr KN. Average effect estimates remain similar as evidence evolves from single trials to high-quality bodies of evidence: a meta-epidemiologic study. J Clin Epidemiol. 2016;69:16–22.
- Kim C-K, Kim D-H, Lee MS, Kim J-I, Wieland LS, Shin B-C. Randomized Controlled Trials on Complementary and Traditional Medicine in the Korean Literature. Evid-Based Complement Alter Med. 2014;2014:194047.
- 32. Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017;22(4):139–42.
- Sterne JA, Jüni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in "meta-epidemiological" research. Stat Med. 2002;21(11):1513–24.
- Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effects estimated in randomized clinical trials. Stat Med. 2007;26(14):2745–58.
- Welton NJ, Ades AE, Carlin JB, Altman DG, Sterne JAC: Models for potentially biased evidence in meta-analysis using empirically based priors. J R Stat Soc. 2009;172(1):119–36.
- Giraudeau B, Higgins JP, Tavernier E, Trinquart L. Sample size calculation for meta-epidemiological studies. Stat Med. 2016;35(2):239–50.
- 37 Herbert RD. Controversy and debate on meta-epidemiology. Paper 2: meta-epidemiological studies of bias may themselves be biased. J Clin Epidemiol. 2020;123:127–30.
- Moustgaard H, Jones HE, Savović J, Clayton GL, Sterne JA, Higgins JP, Hróbjartsson A. Ten questions to consider when interpreting results of a meta-epidemiological study-the MetaBLIND study as a case. Res Synth Methods. 2020;11(2):260–74.
- Lunny C, Pieper D, Thabet P, Kanji S. Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews. BMC Med Res Methodol. 2021;21(1):140.
- Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in "meta-epidemiological" research. Stat Med. 2002;21(11):1513–24.
- Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Can Med Assoc J. 2013;185(4):201–11.
- Page MJ: Confounding and other concerns in meta-epidemiological studies of bias. J Clin Epidemiol. 2020;123:133–4.
- Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed). 2010;340: c332.
- Alba AC, Alexander PE, Chang J, MacIsaac J, DeFry S, Guyatt GH. High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol. 2016;70:129–35.
- Puljak L. Research-on-research studies or methodological studies are primary research. J Clin Epidemiol. 2019;112:95.
- Takwoingi Y, Leeflang MM, Deeks JJ. Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Ann Intern Med. 2013;158(7):544–54.
- van Enst WA, Scholten RJ, Whiting P, Zwinderman AH, Hooft L. Metaepidemiologic analysis indicates that MEDLINE searches are sufficient for diagnostic test accuracy systematic reviews. J Clin Epidemiol. 2014;67(11):1192–9.
- Crowley RJ, Tan YJ, Ioannidis JPA. Empirical assessment of bias in machine learning diagnostic test accuracy studies. J Am Med Inform Assoc: JAMIA. 2020;27(7):1092–101.
- Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ (Clinical research ed). 2011;343: d6829.

- Lu VM, Phan K, Yin JXM, McDonald KL. Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature. J Neurooncol. 2018;139(2):231–8.
- Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence of the impact of study characteristics on the performance of prediction models: a meta-epidemiological study. BMJ Open. 2019;9(4):e026160–e026160.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

